187 related articles for article (PubMed ID: 25565632)
1. The cylindromatosis gene product, CYLD, interacts with MIB2 to regulate notch signalling.
Rajan N; Elliott RJ; Smith A; Sinclair N; Swift S; Lord CJ; Ashworth A
Oncotarget; 2014 Dec; 5(23):12126-40. PubMed ID: 25565632
[TBL] [Abstract][Full Text] [Related]
2. The E3 ubiquitin ligase MIB2 enhances inflammation by degrading the deubiquitinating enzyme CYLD.
Uematsu A; Kido K; Takahashi H; Takahashi C; Yanagihara Y; Saeki N; Yoshida S; Maekawa M; Honda M; Kai T; Shimizu K; Higashiyama S; Imai Y; Tokunaga F; Sawasaki T
J Biol Chem; 2019 Sep; 294(38):14135-14148. PubMed ID: 31366726
[TBL] [Abstract][Full Text] [Related]
3. Dysregulated TRK signalling is a therapeutic target in CYLD defective tumours.
Rajan N; Elliott R; Clewes O; Mackay A; Reis-Filho JS; Burn J; Langtry J; Sieber-Blum M; Lord CJ; Ashworth A
Oncogene; 2011 Oct; 30(41):4243-60. PubMed ID: 21552290
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of MYB drives proliferation of CYLD-defective cylindroma cells.
Rajan N; Andersson MK; Sinclair N; Fehr A; Hodgson K; Lord CJ; Kazakov DV; Vanecek T; Ashworth A; Stenman G
J Pathol; 2016 Jun; 239(2):197-205. PubMed ID: 26969893
[TBL] [Abstract][Full Text] [Related]
5. MIB2 variants altering NOTCH signalling result in left ventricle hypertrabeculation/non-compaction and are associated with Ménétrier-like gastropathy.
Piccolo P; Attanasio S; Secco I; Sangermano R; Strisciuglio C; Limongelli G; Miele E; Mutarelli M; Banfi S; Nigro V; Pons T; Valencia A; Zentilin L; Campione S; Nardone G; Lynnes TC; Celestino-Soper PB; Spoonamore KG; D'Armiento FP; Giacca M; Staiano A; Vatta M; Collesi C; Brunetti-Pierri N
Hum Mol Genet; 2017 Jan; 26(1):33-43. PubMed ID: 28013292
[TBL] [Abstract][Full Text] [Related]
6. Transition from cylindroma to spiradenoma in CYLD-defective tumours is associated with reduced DKK2 expression.
Rajan N; Burn J; Langtry J; Sieber-Blum M; Lord CJ; Ashworth A
J Pathol; 2011 Jul; 224(3):309-21. PubMed ID: 21598248
[TBL] [Abstract][Full Text] [Related]
7. Tropomyosin Receptor Antagonism in Cylindromatosis (TRAC), an early phase trial of a topical tropomyosin kinase inhibitor as a treatment for inherited CYLD defective skin tumours: study protocol for a randomised controlled trial.
Cranston A; Stocken DD; Stamp E; Roblin D; Hamlin J; Langtry J; Plummer R; Ashworth A; Burn J; Rajan N
Trials; 2017 Mar; 18(1):111. PubMed ID: 28270164
[TBL] [Abstract][Full Text] [Related]
8. The LEF1/CYLD axis and cIAPs regulate RIP1 deubiquitination and trigger apoptosis in selenite-treated colorectal cancer cells.
Wu P; Shi KJ; An JJ; Ci YL; Li F; Hui KY; Yang Y; Xu CM
Cell Death Dis; 2014 Feb; 5(2):e1085. PubMed ID: 24577083
[TBL] [Abstract][Full Text] [Related]
9. Loss of the tumor suppressor CYLD enhances Wnt/beta-catenin signaling through K63-linked ubiquitination of Dvl.
Tauriello DV; Haegebarth A; Kuper I; Edelmann MJ; Henraat M; Canninga-van Dijk MR; Kessler BM; Clevers H; Maurice MM
Mol Cell; 2010 Mar; 37(5):607-19. PubMed ID: 20227366
[TBL] [Abstract][Full Text] [Related]
10. CYLD negatively regulates cell-cycle progression by inactivating HDAC6 and increasing the levels of acetylated tubulin.
Wickström SA; Masoumi KC; Khochbin S; Fässler R; Massoumi R
EMBO J; 2010 Jan; 29(1):131-44. PubMed ID: 19893491
[TBL] [Abstract][Full Text] [Related]
11. Mind bomb-2 is an E3 ligase for Notch ligand.
Koo BK; Yoon KJ; Yoo KW; Lim HS; Song R; So JH; Kim CH; Kong YY
J Biol Chem; 2005 Jun; 280(23):22335-42. PubMed ID: 15824097
[TBL] [Abstract][Full Text] [Related]
12. Tumor suppressor cylindromatosis (CYLD) controls HIV transcription in an NF-κB-dependent manner.
Manganaro L; Pache L; Herrmann T; Marlett J; Hwang Y; Murry J; Miorin L; Ting AT; König R; García-Sastre A; Bushman FD; Chanda SK; Young JA; Fernandez-Sesma A; Simon V
J Virol; 2014 Jul; 88(13):7528-40. PubMed ID: 24760882
[TBL] [Abstract][Full Text] [Related]
13. The tumour suppressor CYLD is a negative regulator of RIG-I-mediated antiviral response.
Friedman CS; O'Donnell MA; Legarda-Addison D; Ng A; Cárdenas WB; Yount JS; Moran TM; Basler CF; Komuro A; Horvath CM; Xavier R; Ting AT
EMBO Rep; 2008 Sep; 9(9):930-6. PubMed ID: 18636086
[TBL] [Abstract][Full Text] [Related]
14. New classes of mind bomb-interacting proteins identified from yeast two-hybrid screens.
Tseng LC; Zhang C; Cheng CM; Xu H; Hsu CH; Jiang YJ
PLoS One; 2014; 9(4):e93394. PubMed ID: 24714733
[TBL] [Abstract][Full Text] [Related]
15. The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination.
Kovalenko A; Chable-Bessia C; Cantarella G; Israël A; Wallach D; Courtois G
Nature; 2003 Aug; 424(6950):801-5. PubMed ID: 12917691
[TBL] [Abstract][Full Text] [Related]
16. [Research progress of deubiquitinating enzyme CYLD to regulate liver-related diseases].
Yang X; An DJ; Gao CC; Qin HY
Zhonghua Gan Zang Bing Za Zhi; 2019 Jun; 27(6):477-480. PubMed ID: 31357769
[TBL] [Abstract][Full Text] [Related]
17. CYLD regulates keratinocyte differentiation and skin cancer progression in humans.
Alameda JP; Fernández-Aceñero MJ; Moreno-Maldonado R; Navarro M; Quintana R; Page A; Ramírez A; Bravo A; Casanova ML
Cell Death Dis; 2011 Sep; 2(9):e208. PubMed ID: 21900959
[TBL] [Abstract][Full Text] [Related]
18. Potential role of CYLD (Cylindromatosis) as a deubiquitinating enzyme in vascular cells.
Takami Y; Nakagami H; Morishita R; Katsuya T; Hayashi H; Mori M; Koriyama H; Baba Y; Yasuda O; Rakugi H; Ogihara T; Kaneda Y
Am J Pathol; 2008 Mar; 172(3):818-29. PubMed ID: 18245814
[TBL] [Abstract][Full Text] [Related]
19. The tumor suppressor CYLD regulates entry into mitosis.
Stegmeier F; Sowa ME; Nalepa G; Gygi SP; Harper JW; Elledge SJ
Proc Natl Acad Sci U S A; 2007 May; 104(21):8869-74. PubMed ID: 17495026
[TBL] [Abstract][Full Text] [Related]
20. LUBAC-Recruited CYLD and A20 Regulate Gene Activation and Cell Death by Exerting Opposing Effects on Linear Ubiquitin in Signaling Complexes.
Draber P; Kupka S; Reichert M; Draberova H; Lafont E; de Miguel D; Spilgies L; Surinova S; Taraborrelli L; Hartwig T; Rieser E; Martino L; Rittinger K; Walczak H
Cell Rep; 2015 Dec; 13(10):2258-72. PubMed ID: 26670046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
